Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novartis is one step closer to marketing Lucentis in a new group of patients. The National Institute for Health and Clinical Excellence officially changed its mind on the Swiss drugmaker's eye treatment, recommending the pricey injection for use in diabetics.
The NICE move comes as Lucentis faces new competition from Bayer's Eylea in age-related macular degeneration. Bayer launched the head-to-head competitor in December in the U.K.
To win the new recommendation in patients with diabetic macular edema, Novartis offered a discount--as yet undisclosed--off the usual ?742-per-injection price (about $1,200).
http://www.fiercepharma.com/story/l...e-nod-diabetes-related-vision-loss/2013-01-03
The NICE move comes as Lucentis faces new competition from Bayer's Eylea in age-related macular degeneration. Bayer launched the head-to-head competitor in December in the U.K.
To win the new recommendation in patients with diabetic macular edema, Novartis offered a discount--as yet undisclosed--off the usual ?742-per-injection price (about $1,200).
http://www.fiercepharma.com/story/l...e-nod-diabetes-related-vision-loss/2013-01-03